|
PHLPP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62725388719309E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.88737914186277E-15 |
| Normal-vs-Stage2 |
6.161799959159E-09 |
| Normal-vs-Stage3 |
8.26005930321116E-14 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
7.436100E-02 |
| Stage1-vs-Stage3 |
8.372000E-01 |
| Stage1-vs-Stage4 |
1.090270E-02 |
| Stage2-vs-Stage3 |
1.991380E-01 |
| Stage2-vs-Stage4 |
2.780300E-03 |
| Stage3-vs-Stage4 |
6.384400E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
2.92266211232572E-12 |
| Normal-vs-Asian |
2.22044604925031E-16 |
| Caucasian-vs-AfricanAmerican |
9.411200E-01 |
| Caucasian-vs-Asian |
1.485010E-01 |
| AfricanAmerican-vs-Asian |
3.498800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.99760216648792E-15 |
| Normal-vs-Female |
2.99760216648792E-15 |
| Male-vs-Female |
8.466200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62625468647093E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
4.10782519111308E-15 |
| Normal-vs-Age(81-100Yrs) |
1.819570E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.102400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.956400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.876200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.483400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.977200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.978800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.36010000000242E-05 |
| Classical-VS-Follicular |
1.389040E-01 |
| Classical-VS-Other |
3.450000E-01 |
| Classical-VS-Normal |
2.04281036531029E-14 |
| Tall-VS-Follicular |
7.80500000000517E-05 |
| Tall-VS-Other |
6.071400E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
5.878300E-02 |
| Follicular-VS-Normal |
1.74289471743805E-11 |
| Other-VS-Normal |
2.14419999977622E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
4.261500E-03 |
|
|
